Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during a surgical procedure, and replaces the human dopa decarboxylase (DDC ...

Nina Bhardwaj and Dr. Mesude Bicak, Icahn School of Medicine at Mount Sinai. Targeting dopa decarboxylase (DDC)-dependent metabolic reprogramming to overcome immunotherapy resistance in NEPC ...